83,500 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Trilogy Capital Inc.

Trilogy Capital Inc. acquired a new stake in Humacyte, Inc. (NASDAQ:HUMA) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 83,500 shares of the company’s stock, valued at approximately $422,000. Trilogy Capital Inc. owned approximately 0.07% of Humacyte at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Brookstone Capital Management acquired a new position in shares of Humacyte in the fourth quarter valued at about $56,000. ACT Wealth Management LLC bought a new stake in Humacyte in the 4th quarter valued at about $57,000. Concurrent Investment Advisors LLC bought a new stake in Humacyte in the 3rd quarter valued at about $75,000. FORA Capital LLC acquired a new position in shares of Humacyte during the 3rd quarter worth approximately $96,000. Finally, Insigneo Advisory Services LLC bought a new position in shares of Humacyte during the third quarter worth approximately $109,000. Institutional investors own 44.71% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HUMA. Piper Sandler set a $6.00 price target on Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Benchmark raised their price target on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. TD Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Humacyte has a consensus rating of “Buy” and an average price target of $13.71.

Insiders Place Their Bets

In related news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now owns 2,419,712 shares in the company, valued at $10,743,521.28. This represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is currently owned by insiders.

Humacyte Trading Down 0.7 %

Shares of NASDAQ HUMA opened at $4.27 on Friday. The company has a market cap of $537.42 million, a price-to-earnings ratio of -3.19 and a beta of 1.30. Humacyte, Inc. has a 12 month low of $2.81 and a 12 month high of $9.97. The stock has a 50-day moving average price of $4.53 and a two-hundred day moving average price of $5.46.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). During the same period last year, the business posted ($0.25) EPS. On average, sell-side analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.